DSIP brings sleep. Epitalon brings longevity. Semax brings cognition. All three reach PCAC on July 24.
Tomorrow's PCAC meeting has three names to know: emideltide (DSIP), Epitalon, and Semax.
Together, they give Day 2 a clean story across sleep, longevity, and the brain.
1. Emideltide (DSIP)
DSIP opens the meeting with the strongest sleep identity of the three. FDA reviewed emideltide for chronic insomnia, narcolepsy, and opioid withdrawal.
2. Epitalon
Epitalon brings the longevity audience. The four-amino-acid peptide reaches PCAC with insomnia as the FDA-reviewed use and separate free-base and acetate questions.
Read the Epitalon vote preview.
3. Semax
Semax closes the slate with a neurological focus. FDA reviewed cerebral ischemia, migraine, and trigeminal neuralgia.
Why tomorrow matters
Day 1 produced favorable results for BPC-157, KPV, and TB-500. Day 2 can extend that momentum into three of the peptide world's most followed sleep, longevity, and cognitive compounds.
Watch the July 24 PCAC meeting
The official FDA webcast begins at 8 a.m. Eastern. Watch the PCAC live stream or keep Rebody's live tracker open for results.
Tomorrow's PCAC FAQ
Which three peptides are at PCAC tomorrow?
Emideltide (DSIP), Epitalon, and Semax.
What time does the meeting start?
The July 24 PCAC meeting begins at 8 a.m. Eastern.
Where can I follow the votes?
Rebody's live tracker includes the official FDA webcast and current peptide results.